文献速递白血病

CXCR4作为急性髓系白血病的治疗靶点

CXCR4 as a therapeutic target in acute myeloid leukemia.
PubMed 文献 · Leukemia · 2024-09-11

本文综述了CXCL12-CXCR4轴在急性髓系白血病(AML)致癌过程中的分子机制与临床意义,涵盖对自主增殖、凋亡调控、化疗耐药及与间充质干细胞和调节性T细胞相互作用的影响,并讨论了该轴的预后价值及与FLT3-ITD、NPM1突变和FAB分型的关联,最后评述了plerixafor/AMD3100、ulocuplumab、肽E5和motixafortide等靶向该轴的药物在AML治疗中的潜在价值。

要点

  • CXCL12-CXCR4轴参与AML的自主增殖、凋亡调控和化疗耐药机制。
  • 该轴与MSCs和Treg细胞等非白血病细胞相互作用,影响白血病微环境。
  • 靶向CXCL12-CXCR4轴的药物包括plerixafor/AMD3100、ulocuplumab、肽E5和motixafortide,具有潜在治疗价值。

核心结论

  • 针对CXCL12-CXCR4轴的新型抗白血病药物已被纳入AML治疗策略,但尚缺乏全面且更新的综述来阐述该轴在AML致癌过程中的作用,本文对此进行了系统梳理。

研究设计与样本

  • 本文为综述,检索并汇总了关于CXCL12-CXCR4轴在急性髓系白血病中分子机制、临床意义及靶向药物的相关研究。

主要发现

  • CXCL12-CXCR4轴影响AML细胞的自主增殖、凋亡调控和化疗耐药机制。
  • 该轴与间充质干细胞(MSCs)和调节性T细胞(Treg细胞)等非白血病细胞存在相互作用。
  • CXCR4与AML预后、白细胞计数、骨髓和外周血原始细胞计数相关,并与FLT3-ITD、NPM1突变及FAB分类相关。

关键数值与推荐

  • 靶向CXCL12-CXCR4轴的药物包括plerixafor/AMD3100、ulocuplumab、肽E5和motixafortide。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Extensive research on the CXCL12-CXCR4 axis in acute myeloid leukemia (AML) has resulted in the incorporation of novel anti-leukemia drugs targeting this axis into therapeutic strategies. However, despite this progress, a comprehensive and up-to-date review addressing the role of the CXCL12-CXCR4 axis in AML's oncogenic processes is lacking. In this review, we examine its molecular aspects influencing cancer progression, such as its impact on autonomous proliferation, apoptotic regulation, chemoresistance mechanisms, and interactions with non-leukemic cells such as MSCs and Treg cells. Additionally, we explore clinical implications, including prognosis, correlation with WBC count, blast count in the bone marrow and peripheral blood, as well as its association with FLT3-ITD, NPM1 mutations, and FAB classification. Finally, this paper extensively discusses drugs that specifically target the CXCL12-CXCR4 axis, including plerixafor/AMD3100, ulocuplumab, peptide E5, and motixafortide, shedding light on their potential therapeutic value in the treatment of AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Korbecki J, Bosiacki M, Kupnicka P, et al. CXCR4 as a therapeutic target in acute myeloid leukemia. Leukemia. 2024. PMID: 39261603. doi:10.1038/s41375-024-02326-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。